Citation: | LYU Zhengqin, ZHAO Yuhao, GUO Yuanyuan, LIU Beibei, LIU Jianmin. Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 394-399. DOI: 10.12290/xhyxzz.2023-0488 |
[1] |
Kim T K, Herbst R S, Chen L P. Defining and unders-tanding adaptive resistance in cancer immunotherapy[J]. Trends Immunol, 2018, 39(8): 624-631. DOI: 10.1016/j.it.2018.05.001
|
[2] |
Hopkins A M, Kichenadasse G, Karapetis C S, et al. Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab[J]. Eur Urol, 2020, 78(4): 540-543. DOI: 10.1016/j.eururo.2020.06.061
|
[3] |
Lopes S, Pabst L, Dory A, et al. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis[J]. Front Immunol, 2023, 14: 1070076. DOI: 10.3389/fimmu.2023.1070076
|
[4] |
Drakaki A, Dhillon P K, Wakelee H, et al. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune check-point inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma[J]. Oncoimmunology, 2020, 9(1): 1824645. DOI: 10.1080/2162402X.2020.1824645
|
[5] |
Kokolus K M, Zhang Y, Sivik J M, et al. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice[J]. Oncoimmunology, 2018, 7(3): e1405205. DOI: 10.1080/2162402X.2017.1405205
|
[6] |
Fiala O, Buti S, Takeshita H, et al. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study[J]. Cancer Immunol Immunother, 2023, 72(11): 3665-3682. DOI: 10.1007/s00262-023-03518-z
|
[7] |
Weersma R K, Zhernakova A, Fu J Y. Interaction between drugs and the gut microbiome[J]. Gut, 2020, 69(8): 1510-1519. DOI: 10.1136/gutjnl-2019-320204
|
[8] |
Matson V, Fessler J, Bao R Y, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients[J]. Science, 2018, 359(6371): 104-108. DOI: 10.1126/science.aao3290
|
[9] |
Ubeda C, Pamer E G. Antibiotics, microbiota, and immune defense[J]. Trends Immunol, 2012, 33(9): 459-466. DOI: 10.1016/j.it.2012.05.003
|
[10] |
Tsikala-Vafea M, Belani N, Vieira K, et al. Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis[J]. Int J Infect Dis, 2021, 106: 142-154. DOI: 10.1016/j.ijid.2021.03.063
|
[11] |
Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371): 91-97. DOI: 10.1126/science.aan3706
|
[12] |
Wu Q, Liu J J, Wu S M, et al. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: a study based on 44 cohorts[J]. Int Immunopharmacol, 2021, 92: 107303. DOI: 10.1016/j.intimp.2020.107303
|
[13] |
Sivan A, Corrales L, Hubert N, et al. Commensal Bifido-bacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J]. Science, 2015, 350(6264): 1084-1089. DOI: 10.1126/science.aac4255
|
[14] |
Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients[J]. Science, 2018, 359(6371): 104-108. DOI: 10.1126/science.aao3290
|
[15] |
Casadei C, Lolli C, Farolfi A. Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics[J]. Ann Transl Med, 2019, 7(Suppl 8): S339.
|
[16] |
Rosa R G, Goldani L Z, Dos Santos R P. Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study[J]. BMC Infect Dis, 2014, 14: 286. DOI: 10.1186/1471-2334-14-286
|
[17] |
Routy B, Gopalakrishnan V, Daillère R, et al. The gut microbiota influences anticancer immunosurveillance and general health[J]. Nat Rev Clin Oncol, 2018, 15(6): 382-396. DOI: 10.1038/s41571-018-0006-2
|
[18] |
Esteves M, Rollason V, Grosgurin O. Proton pump inhibi-tors overprescription[J]. Rev Med Suisse, 2017, 13(579): 1782-1786.
|
[19] |
Reveles K R, Ryan C N, Chan L, et al. Proton pump inhibitor use associated with changes in gut microbiota composition[J]. Gut, 2018, 67(7): 1369-1370. DOI: 10.1136/gutjnl-2017-315306
|
[20] |
Hojo M, Asahara T, Nagahara A, et al. Gut microbiota composition before and after use of proton pump inhibitors[J]. Dig Dis Sci, 2018, 63(11): 2940-2949. DOI: 10.1007/s10620-018-5122-4
|
[21] |
Hopkins A M, Kichenadasse G, Karapetis C S, et al. Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab[J]. Clin Cancer Res, 2020, 26(20): 5487-5493. DOI: 10.1158/1078-0432.CCR-20-1876
|
[22] |
Zhang L L, Chen C, Chai D Q, et al. Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy[J]. Front Pharmacol, 2022, 13: 1018411. DOI: 10.3389/fphar.2022.1018411
|
[23] |
Rizzo A, Santoni M, Mollica V, et al. The impact of concomitant proton pump inhibitors on immunotherapy efficacy among patients with urothelial carcinoma: a meta-analysis[J]. J Pers Med, 2022, 12(5): 842. DOI: 10.3390/jpm12050842
|
[24] |
Okuyama Y, Hatakeyama S, Numakura K, et al. Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma[J]. BJUI Compass, 2022, 3(2): 154-161. DOI: 10.1002/bco2.118
|
[25] |
Kunimitsu Y, Morio K, Hirata S, et al. Effects of proton pump inhibitors on survival outcomes in patients with metastatic or unresectable urothelial carcinoma treated with pembrolizumab[J]. Biol Pharm Bull, 2022, 45(5): 590-595. DOI: 10.1248/bpb.b21-00939
|
[26] |
Gong J, Chehrazi-Raffle A, Placencio-Hickok V, et al. The gut microbiome and response to immune checkpoint inhibi-tors: preclinical and clinical strategies[J]. Clin Transl Med, 2019, 8(1): 9. DOI: 10.1186/s40169-019-0225-x
|
[27] |
Gopalakrishnan V, Spencer C N, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018, 359(6371): 97-103. DOI: 10.1126/science.aan4236
|
[28] |
Laheij R J F, Sturkenboom M C J M, Hassing R J, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs[J]. JAMA, 2004, 292(16): 1955-1960. DOI: 10.1001/jama.292.16.1955
|
[29] |
Skribek M, Rounis K, Afshar S, et al. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors[J]. Eur J Cancer, 2021, 145: 245-254. DOI: 10.1016/j.ejca.2020.12.012
|
[30] |
Petrelli F, Signorelli D, Ghidini M, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. Cancers (Basel), 2020, 12(3): 546. DOI: 10.3390/cancers12030546
|
[31] |
Chen C Y, Rao S S, Yue T, et al. Glucocorticoid-induced loss of beneficial gut bacterial extracellular vesicles is associated with the pathogenesis of osteonecrosis[J]. Sci Adv, 2022, 8(15): eabg8335. DOI: 10.1126/sciadv.abg8335
|
[32] |
Fucà G, Galli G, Poggi M, et al. Modulation of peripheral blood immune cells by early use of steroids and its associa-tion with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors[J]. ESMO Open, 2019, 4(1): e000457. DOI: 10.1136/esmoopen-2018-000457
|
[33] |
Spakowicz D, Hoyd R, Muniak M, et al. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications[J]. BMC Cancer, 2020, 20(1): 383. DOI: 10.1186/s12885-020-06882-6
|
[34] |
Ricciuti B, Dahlberg S E, Adeni A, et al. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications[J]. J Clin Oncol, 2019, 37(22): 1927-1934. DOI: 10.1200/JCO.19.00189
|
[35] |
Horvat T Z, Adel N G, Dang T O, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center[J]. J Clin Oncol, 2015, 33(28): 3193-3198. DOI: 10.1200/JCO.2015.60.8448
|
[36] |
Robesti D, Nocera L, Belladelli F, et al. The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials[J]. BJU Int, 2024, 133(2): 158-168. DOI: 10.1111/bju.16121
|
[37] |
Maxwell R, Luksik A S, Garzon-Muvdi T, et al. Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nerv-ous system[J]. Oncoimmunology, 2018, 7(12): e1500108. DOI: 10.1080/2162402X.2018.1500108
|
[38] |
Oh M S, Guzner A, Wainwright D A, et al. The impact of beta blockers on survival outcomes in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors[J]. Clin Lung Cancer, 2021, 22(1): e57-e62. DOI: 10.1016/j.cllc.2020.07.016
|
[39] |
Bucsek M J, Qiao G X, MacDonald C R, et al. β-adren-ergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8+ T cells and under-mines checkpoint inhibitor therapy[J]. Cancer Res, 2017, 77(20): 5639-5651. DOI: 10.1158/0008-5472.CAN-17-0546
|
[40] |
Mellgard G, Patel V G, Zhong X B, et al. Effect of concurrent beta-blocker use in patients receiving immune check-point inhibitors for advanced solid tumors[J]. J Cancer Res Clin Oncol, 2023, 149(7): 2833-2841. DOI: 10.1007/s00432-022-04159-y
|
[41] |
Rains S L, Amaya C N, Bryan B A. Beta-adrenergic receptors are expressed across diverse cancers[J]. Oncoscience, 2017, 4(7/8): 95-105.
|
[42] |
Udumyan R, Botteri E, Jerlstrom T, et al. Beta-blocker use and urothelial bladder cancer survival: a Swedish register-based cohort study[J]. Acta Oncol, 2022, 61(8): 922-930. DOI: 10.1080/0284186X.2022.2101902
|
[43] |
Scharping N E, Menk A V, Whetstone R D, et al. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia[J]. Cancer Immunol Res, 2017, 5(1): 9-16. DOI: 10.1158/2326-6066.CIR-16-0103
|
[44] |
Gandhi S, Pandey M, Ammannagari N, et al. Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors[J]. Immunotherapy, 2020, 12(2): 141-149. DOI: 10.2217/imt-2019-0064
|
[45] |
Afzal M Z, Mercado R R, Shirai K. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma[J]. J Immunother Cancer, 2018, 6(1): 64. DOI: 10.1186/s40425-018-0375-1
|
[46] |
Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug[J]. Nat Med, 2017, 23(7): 850-858. DOI: 10.1038/nm.4345
|
[47] |
Liu W H, Wang Y, Luo J Q, et al. Pleiotropic effects of metformin on the antitumor efficiency of immune checkpoint inhibitors[J]. Front Immunol, 2020, 11: 586760.
|
[48] |
Zhang J J, Zhang Q S, Li Z Q, et al. Metformin attenuates PD-L1 expression through activating Hippo signaling pathway in colorectal cancer cells[J]. Am J Transl Res, 2019, 11(11): 6965-6976.
|
[49] |
Kim H, Seol Y M, Choi Y J, et al. HMG CoA reductase expression as a prognostic factor in Korean patients with breast cancer: A retrospective study[J]. Medicine (Baltimore), 2019, 98(13): e14968. DOI: 10.1097/MD.0000000000014968
|
[50] |
Cantini L, Pecci F, Hurkmans D, et al. Statin treatment improves response to anti-PD1 agents in patients with malignant pleural mesothelioma and non-small cell lung cancer[J]. J Clin Oncol, 2020, 38(15_suppl): 3074. DOI: 10.1200/JCO.2020.38.15_suppl.3074
|
[51] |
Cantini L, Pecci F, Hurkmans D P, et al. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients[J]. Eur J Cancer, 2021, 144: 41-48. DOI: 10.1016/j.ejca.2020.10.031
|
[52] |
Choe E J, Lee C H, Bae J H, et al. Atorvastatin enhances the efficacy of immune checkpoint therapy and suppresses the cellular and extracellular vesicle PD-L1[J]. Pharmaceutics, 2022, 14(8): 1660. DOI: 10.3390/pharmaceutics14081660
|
[1] | NIMA Zhuoma, XIAO Yu, LUO Hanhuan, DUO Bula, WANG Han, DA Zhen, SILANG Jiangcun, GUO Pingping, LIAO Ruiqian. Expression and Significance of GATA-3, H3K27me3 in Tibetan Patients with Bladder Urothelial Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 953-959. DOI: 10.12290/xhyxzz.2023-0595 |
[2] | YAN Xinchun, HUO Li. Evaluation of Von Hippel-Lindau Syndrome Through Novel Small Molecular Tracer 68Ga-NY104 PET/CT Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 911-915. DOI: 10.12290/xhyxzz.2024-0216 |
[3] | YANG Tingkai, WEN Jin, JI Zhigang. The Value of Insulin-like Growth Factor 2 in Urinary Exosomes of Bladder Urothelial Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 632-636. DOI: 10.12290/xhyxzz.2021-0446 |
[4] | DAI Liyuan, SHI Yuankai, HAN Xiaohong. Advances in Dynamic Monitoring of Immune Checkpoint Inhibitors as the Prognostic Markers for Advanced Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 287-295. DOI: 10.12290/xhyxzz.2021-0608 |
[5] | Gynecological Oncology Society of Chinese Medical Association. Clinical Practice Guidelines for Immune Checkpoint Inhibitor Therapy in Gynecological Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 854-880. DOI: 10.12290/xhyxzz.2021-0683 |
[6] | WU Ling-ge, XU Yan, LI Nai-shi. Thyrotoxicosis Related to Immune Checkpoint Inhibitors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 129-135. DOI: 10.3969/j.issn.1674-9081.2020.00.004 |
[7] | Yang GAO, Zhao SUN, Chun-mei BAI. Application of Immune-checkpoint Inhibitors in Recurrent/Metastatic Nasopharyngeal Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 626-630. DOI: 10.3969/j.issn.1674-9081.2020.05.021 |
[8] | Hui TANG, Jian-feng ZHOU, Chun-mei BAI. Clinical Progress of Immune Checkpoint Inhibitors in the Elderly[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 459-464. DOI: 10.3969/j.issn.1674-9081.2020.04.018 |
[9] | Ming-yang LIU, Jie CHEN, Jian GUAN. Local Injections of Cholesterol-conjugated let-7a Mimics Inhibit Tumor Growth and Metastasis of Hepatocellular Carcinoma in a Subcutaneous Xenograft Nude Mouse Model by Targeting K-Ras, H-Ras, and N-Ras[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(2): 133-139. DOI: 10.3969/j.issn.1674-9081.2015.02.012 |
[10] | Jie SHI, Zhi-yong LIANG, Tong-hua LIU. Expression of Cyclin D1 in Invasive Lobular Carcinoma of the Breast and Its Significance[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(1): 8-12. DOI: 10.3969/j.issn.1674-9081.2012.01.004 |